Patent Assignment
Reel/Frame 030603/0924
Merger
Recorded: 2013-06-13
Pages: 7
Assignor
MEDAREX, INC.
Executed: 2012-12-31
Assignee
MEDAREX, L.L.C.
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NEW JERSEY, 08540
Covered Properties
(116)
Water-Soluble Polypeptides Having a High Affinity for Alpha and Beta Interferons
Patent:
6,475,983 →
Application:
07/971,834 →
Monoclonal Antibodies Against the Interferon Receptor, with Neutralizing Activity Against Type I Interferon
Patent:
5,919,453 →
Application:
08/307,588 →
Purified Human Alpha Interferon Receptor
Patent:
5,889,151 →
Application:
08/453,090 →
Use of the Alpha Interferon Receptor and Cells Which Express the Receptor, for Identification of Alpha Interferon Agonists
Patent:
5,861,258 →
Application:
08/466,974 →
Antibodies Directed Against the Alhpa Interferon Receptor
Patent:
5,886,153 →
Application:
08/471,453 →
Cdna Fragment Coding the Alpha Interferon Receptor Gene and Process for the Preparation of a Corresponding Protein
Patent:
5,731,169 →
Application:
08/471,454 →
Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Specific Membrane Antigen
Patent:
6,150,508 →
Application:
09/044,668 →
Isolated Peptide or Polypeptide of the Extracellular Portion of the Human Interferon Receptor (Ifn-R)
Therapeutic Compounds Comprised of Anti-Fc Receptor Binding Agents
Patent:
6,365,161 →
Application:
09/364,088 →
Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Specific Membrane Antigen
Patent:
7,381,407 →
Application:
09/561,462 →
Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Spcific Membrane Antigen
Patent:
6,962,981 →
Application:
09/561,502 →
Enzyme-Cleavable Prodrug Compounds
Cytotoxic Agents
Disulfide Prodrugs and Linkers and Stabilizers Useful Therefor
Peptidyl Prodrugs and Linkers and Stabilizers Useful Therefor
CD10-Activated Prodrug Compounds
Prodrug Compounds with an Isoleucine
Tripeptide Prodrug Compounds
Use of Biomolecular Targets in the Treatment and Visualization of Tumors
Use of Biomolecular Targets in the Treatment and Visualization of Brain Tumors
Human Monoclonal Antibodies Against CD30
Prodrugs Activated by Plasmin and Their Use in Cancer Chemotherapy
Methods of Treatment Using Ctla-4 Antibodies
Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-Specific Membrane Antigen
Use of Protein Biomolecular Targets in the Treatment and Visualization of Brain Tumors
Monoclonal Antibodies Against the Interferon Receptor, with Neutralizing Activity Against Type I Interferon
Methods for the Therapy of Inflammatory Bowel Disease Using a Type-1 Interferon Antagonist
Humanized Antibodies to Interferon Alpha Receptor-1 (Ifnar-1)
Human Monoclonal Antibodies Against Bacillus Anthracis Protective Antigen
Surrogate Therapeutic Endpoint for Anti-CTLA4-Based Immunotherapy of Disease
Expression Vector
Anti-Interferon Alpha Antibodies
Cd-10 Activated Prodrug Compounds
Disulfide Prodrugs and Linkers and Stabilizers Useful Therefor
Cytotoxic Compounds and Conjugates
Chemical Linkers and Conjugates Thereof
Monoclonal Antibody Specific for the Extracellular Domain of Prostate Specific Membrane Antigen
Interferon Alpha Receptor 1 Antibodies and Their Uses
Peptidyl Prodrugs and Linkers and Stabilizers Useful Therefor
Method of Treating CD30 Positive Lymphomas
Cytotoxic Compounds and Conjugates with Cleavable Substrates
Prodrug Compounds with Isoleucine
Ctla-4 Antibody Dosage Escalation Regimens
Monoclonal Antibodies Against the Interferon Receptor, with Neutralizing Activity Against Type I Interferon
Tripeptide Prodrug Compounds
Human Monoclonal Antibodies to Programmed Death Ligand 1 (Pd-L1)
CD19 Antibodies and Their Uses
Protein Purification Using Hcic and Ion Exchange Chromatography
Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues
Monoclonal Antibodies Against Prostate Specific Membrane Antigen (Psma) Lacking in Fucosyl Residues
CD10-Activated Prodrug Compounds
Prodrug Compounds with Isoleucine
Human Monoclonal Antibodies to CD70
Human Monoclonal Antibodies Against CD30
Methods and Compounds for Preparing Cc-1065 Analogs
Cytotoxic Compounds and Conjugates
Human Monoclonal Antibodies to O8E
Human Monoclonal Antibodies to Fucosyl-GM1 and Methods for Using Anti-Fucosyl-GM1
Human Monoclonal Antibodies to Protein Tyrosine Kinase 7 (PTK7) and Methods for Using Anti-PTK7 Antibodies
Peptidyl Prodrugs and Linkers and Stabilizers Useful Therefor
Patent:
41,252 →
Application:
12/126,731 →
Methods for Characterizing Glycosylation Sites
Prodrugs Activated by Plasmin and Their Use in Cancer Chemotherapy
Enzyme-Cleavable Prodrug Compounds
Methods of Treatment Using Ctla-4 Antibodies
Human Monoclonal Antibodies Against Bacillus Anthracis Protective Antigen
Surrogate Therapeutic Endpoint for Anti-Ctla-4 Based Immunotherapy of Disease
Protein Purification
Application:
12/293,732 →
Publication:
US 2010/0190210
Transgenic Animals Expressing Chimeric Antibodies for Use in Preparing Human Antibodies
Methods of Treating Cancer with an Antibody-Drug Conjugate
Peptidyl Prodrugs and Linkers and Stabilizers Useful Therefor
Human Monoclonal Antibodies That Bind CXCR4
Ip-10 Antibodies and Their Uses
Human Monoclonal Antibodies to Btla and Methods of Use
Human Antibodies That Bind CD22 and Uses Thereof
Human Antibodies That Bind CD70 and Uses Thereof
Application:
12/518,838 →
Publication:
US 2010/0150950
Chemical Linkers and Cleavable Substrates and Conjugates Thereof
Chemical Linkers with Single Amino Acids and Conjugates Thereof
Interferon Alpha Antibodies and Their Uses
Humanized Antibodies to Interferon Alpha Receptor-1 (Ifnar-1)
Methods of Gene Amplification and Expression
Chemical Linkers and Conjugates Thereof
Monoclonal Antibodies Against Glypican-3
HCO32 and HCO27 and Related Examples
Site-Specific Attachment of Drugs or Other Agents to Engineered Antibodies with C-Terminal Extensions
Interferon Alpha Receptor I Antibodies And Their Use
Antiproliferative Compounds, Conjugates Thereof, Methods Therefor, and Uses Thereof
Anti-Ctla-4 Antibodies with Reduced Blocking of Binding of Ctla-4 to B7 and Uses Thereof
Monoclonal Antibodies Against Prostate Specific Membrane Antigen (Psma) Lacking in Fucosyl Residues
Humanized Antibodies to Interferon Alpha Receptor-1 (Ifnar-1)
Transgenic Animals Expressing Chimeric Antibodies for Use in Preparing Human Antibodies
Methods for the Therapy of Inflammatory Bowel Disease Using a Type-1 Interferon Antagonist
Human Antibodies That Bind Lymphocyte Activation Gene-3 (Lag-3) and Uses Thereof
Application:
13/058,492 →
Publication:
US 2011/0150892
Nucleic Acids Encoding Monoclonal Antibodies to Programmed Death Ligand 1 (Pd-L1)
Neuropilin-1 Inhibitors
Application:
13/166,581 →
Publication:
US 2012/0058117
Monoclonal Antibodies to Programmed Death 1 (Pd-1)
Interferon Alpha Antibodies And Their Uses
Ctla-4 Antibody Dosage Escalation Regimens
Fully Human Antibodies to Btla
Protein Purification Using Hcic and Ion Exchange Chromatography
Treating Lung Cancer Using Human Monoclonal Antibodies to Protein Tyrosine Kinase 7 (PTK7)
Monoclonal Antibodies Against CD30 Lacking in Fucosyl Residues
Human Monoclonal Antibodies to Protein Tyrosine Kinase 7 (PTK7)
Ip-10 Antibodies and Their Uses
Cation Exchange Chromatography (Methods)
Application:
13/497,846 →
Publication:
US 2012/0178910
Methods for Enhanced Protein Production
Transgenic Animals Expressing Chimeric Antibodies for Use in Preparing Human Antibodies
Human Monoclonal Antibodies to Btla and Methods of Use
Fully Human Antibodies Specific to CADM1
Application:
13/728,059 →
Publication:
US 2013/0156788
Methods Of Gene Amplification And Expression
Application:
13/740,694 →
Publication:
US 2013/0252327
Human Monoclonal Antibodies to Fucosyl-GM1 and Methods for Using Anti-Fucosyl-GM1 Antibodies
Human Monoclonal Antibodies to Programmed Death Ligand 1 (Pd-L1)
Antiproliferative Compounds, Conjugates Thereof, Methods Therefor, and Uses Thereof
Antiproliferative Compounds, Conjugates Thereof, Methods Therefor, and Uses Thereof
Antiproliferative Compounds, Conjugates Thereof, Methods Therefor, and Uses Thereof
Human Antibodies That Bind CD22 and Uses Thereof
Nucleic Acids Encoding Human Monoclonal Antibodies That Bind CXCR4
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 5, 1994
From: BENOIT, PATRICK; MEYER, FRANCOIS; MAGUIRE, DEBORAH; PLAVEC, IVAN
To: LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE S.A.
Reel/Frame 007315/0536 →
Assignment of Assignor's Interest
Jul 24, 1997
From: EID, PIERRE; MEYER, FRANCOIS; GRESSER, ION; TOVEY, MICHAEL
To: LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE
Reel/Frame 008623/0726 →
Assignment of Assignor's Interest
Jun 2, 1998
From: MURPHY, GERALD P.; BOYNTON, ALTON L.; HOLMES, ERIC H.; TINO, WILLIAM THOMAS
To: PACIFIC NORTHWEST CANCER FOUNDATION
Reel/Frame 009455/0707 →
Assignment of Assignor's Interest
Feb 19, 1999
From: PACIFIC NORTHWEST CANCER FOUNDATION
To: NORTHWEST BIOTHERAPEUTICALS, INC.
Reel/Frame 009783/0233 →
Assignment of Assignor's Interest
Sep 10, 1999
From: LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE
To: MEDISUP INTERNATIONAL N.V.
Reel/Frame 010226/0109 →
Assignment of Assignor's Interest
Nov 8, 1999
From: DEO, YASHWANT M.; GOLDSTEIN, JOEL; GRAZIANO, ROBERT; KELER, TIBOR
To: MEDAREX, INC.
Reel/Frame 010369/0993 →
"Document Previously Recorded at Reel 10226, Frames 0109-0114 Contained an Error in Property Number 5,595,193. Document Rerecorded to Correct Error on Stated Reel".
Feb 17, 2000
From: LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE
To: MEDISUP INTERNATIONAL N.V.
Reel/Frame 010609/0344 →
Assignment of Assignor's Interest
Mar 10, 2000
From: LABORATOIRE EUROPEEN DE BIOTECHNOLOGIE
To: MEDISUP INTERNATIONAL N.V.
Reel/Frame 010682/0671 →
Assignment of Assignor's Interest
Nov 19, 2001
From: GANGWAR, SANJEEV; LOBL , THOMAS J.; NIEDER, MATTHEW H.; PICKFORD, LESLEY B.
To: COULTER PHARMACEUTICAL INC.
Reel/Frame 012311/0785 →
Assignment of Assignor's Interest
Oct 9, 2002
From: NG, HOWARD P.; LI, ZHIHONG; MCGEE, DANNY P.C.; SAUNDERS, OLIVER L.
To: MEDAREX, INC.
Reel/Frame 013378/0797 →
Assignment of Assignor's Interest
Oct 9, 2002
From: NG, HOWARD P.; MCGEE, DANNY P.C.; SAUNDERS, OLIVER L.; MARTICHONOK, VALERI
To: MEDAREX, INC.
Reel/Frame 013378/0779 →
Assignment of Assignor's Interest
Oct 25, 2002
From: NG, HOWARD P.; MCGEE, DANNY P. C.; WU, GUOXIAN; MOORE, JIMMIE
To: MEDAREX, INC.
Reel/Frame 013444/0433 →
Corrective Assignment to Correct Execution Dates, Previously Recorded at Reel 013378, Frame 0797.
Apr 4, 2003
From: NG, HOWARD P.; LI, ZHIHONG; MCGEE, DANNY P.C.; SAUNDERS, OLIVER L.
To: MEDAREX, INC.
Reel/Frame 013923/0559 →
Assignment of Assignor's Interest
Apr 14, 2003
From: MUELLER, SABINE; GONZALEZ-ZULUETA, MIRELLA; FOEHR, ERIK; CHIN, DANIEL J.
To: AGY THERAPEUTICS, INC.
Reel/Frame 013946/0782 →
Assignment of Assignor's Interest
Apr 18, 2003
From: MUELLER, SABINE; GONZALEZ-ZULUETA, MIRELLA; FOEHR, ERIK; CHIN, DANIEL J.
To: AGY THERAPEUTICS, INC.
Reel/Frame 013583/0911 →
Assignment of Assignor's Interest
May 30, 2003
From: BEBBINGTON, CHRISTOPHER R.; NIEDER, MATTHEW H.; CARDARELLI, PINA M.; GANGWAR, SANJEEV
To: MEDAREX, INC.
Reel/Frame 014115/0276 →
Assignment of Assignor's Interest
Jun 12, 2003
From: COULTER PHARMACEUTICAL, INC.
To: MEDAREX, INC.
Reel/Frame 014163/0804 →
Assignment of Assignor's Interest
Aug 21, 2003
From: NORTHWEST BIOTHERAPEUTICS, INC.
To: MEDAREX, INC.
Reel/Frame 014420/0073 →
Assignment of Assignor's Interest
Nov 10, 2003
From: COULTER PHARMACEUTICAL, INC.
To: MEDAREX, INC.
Reel/Frame 015477/0213 →
Assignment of Assignor's Interest
Dec 31, 2003
From: NORTHWEST BIOTHERAPEUTICS, INC.
To: MEDAREX, INC.
Reel/Frame 014836/0779 →
Security Agreement
Apr 27, 2004
From: NORTHWEST BIOTHERAPEUTICS, INC.
To: TOUCAN CAPITAL FUND II, L.P.
Reel/Frame 014567/0206 →
Security Agreement
Sep 8, 2004
From: NORTHWEST BIOTHERAPEUTICS, INC.
To: TOUCAN CAPITAL FUND II, L.P.
Reel/Frame 015093/0483 →
Assignment of Assignor's Interest
Oct 12, 2004
From: COULTER PHARMACEUTICAL, INC.
To: MEDAREX, INC.
Reel/Frame 015237/0850 →
Assignment of Assignor's Interest
Jan 25, 2005
From: MEDISUP INTERNATIONAL N.V.
To: MEDAREX, INC.
Reel/Frame 015612/0810 →
Security Agreement
Jan 13, 2006
From: AGY THERAPEUTICS, INC.
To: GENERAL ELECTRIC CAPITAL CORPORATION
Reel/Frame 017015/0108 →